MeiraGTx Holdings "announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general corporate purposes."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGTX:
- MeiraGTx announces upcoming presentations at ARVO 2023 meeting
- MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
- MeiraGTx to Participate in Upcoming Investor Conferences
- MeiraGTx price target lowered to $22 from $27 at RBC Capital
- MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results